Please login to the form below

Not currently logged in
Email:
Password:

eosinophilic

This page shows the latest eosinophilic news and features for those working in and with pharma, biotech and healthcare.

Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis

Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the European Commission as the first and only targeted medicine for eosinophilic oesophagitis (EoE), the companies announced.

Latest news

More from news
Approximately 7 fully matching, plus 54 partially matching documents found.

Latest Intelligence

  • Exploring the potential of eosinophils Exploring the potential of eosinophils

    Having too many eosinophils in certain tissues is an important contributor to a range of conditions including severe eosinophilic asthma (SEA), nasal polyps, eosinophilic oesophagitis and rarer, systemic diseases such as ... Interestingly, Howarth

  • Gut instincts lead Takeda to GI pipeline success Gut instincts lead Takeda to GI pipeline success

    It also plans to achieve the first FDA therapy approval to treat eosinophilic oesophagitis, a chronic, allergic condition with little current respite.

  • GSK forges ahead with its dynamic COPD and asthma portfolio GSK forges ahead with its dynamic COPD and asthma portfolio

    mepolizumab to treat COPD exacerbations with eosinophilic inflammation. ... You would imagine coronavirus would be one of those threats.”. GSK is trialling its biologic anti IL-5 drug mepolizumab, licensed for severe asthma, in eosinophilic COPD with a

  • The long and winding road to asthma breakthroughs The long and winding road to asthma breakthroughs

    GSK is also anticipating data in hyper-eosinophilic syndrome and nasal polyposis which could lead to commercial approvals in both by the end of 2020. ... Severe eosinophilic asthma (SEA) impacts between 5-10% of the population but they, and other severe

  • Pharma deals in August 2015 Pharma deals in August 2015

    Baxalta aside, it has been a busy year for Shire which in February acquired the company Meritage bringing in a phase III ready oral budesonide solution for eosinophilic oesophagitis [an orphan

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest from PMHub

  • Article

    Inhale, Exhale: The struggle of living with Severe Asthma and Severe Eosinophilic Asthma. ... Head of “Living With”, Mariel Metcalfe, discusses the nature of severe asthma and severe eosinophilic asthma, and some key findings from recent studies

  • Research Partnership Research Partnership

    Inhale, Exhale: The struggle of living with Severe Asthma and Severe Eosinophilic Asthma.

More from PMHub
Approximately 1 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Genesis Research

Genesis Research is an international HEOR and RWE research organization. A leader in evidence strategy, generation and communication, the company...

Latest intelligence

World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
Strategic behaviour
Strong strategising depends on your colleagues’ behaviour...
Pharmaceutical Marketing Strategies For The Digital Age
In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...